Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 11/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.49 |
| ▸ | MRGPRX2 | Q96LB1 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Asalhydromorphone SCHEMBL31237072 | 1.00 | OPRD1 (0.53) | OPRD1OPRM1OPRK1MRGPRX2LMNA | |
| Asalhydromorphone SCHEMBL15028750 | 1.00 | OPRD1 (0.53) | OPRD1OPRM1OPRK1MRGPRX2LMNA | |
| SCHEMBL20077628 | 0.95 | OPRD1 (0.48) | OPRD1OPRM1OPRK1MRGPRX2LMNA | |
| SCHEMBL20077473 | 0.93 | OPRD1 (0.49) | OPRD1OPRM1OPRK1MRGPRX2LMNA | |
| SCHEMBL16922127 | 0.91 | OPRD1 (0.59) | OPRD1OPRM1OPRK1MRGPRX2LMNA | |
| SCHEMBL20077664 | 0.88 | OPRD1 (0.51) | OPRD1OPRM1OPRK1MRGPRX2LMNA | |
| SCHEMBL15028743 | 0.87 | OPRD1 (0.49) | OPRD1OPRM1OPRK1MRGPRX2LMNA | |
| SCHEMBL20077663 | 0.86 | OPRD1 (0.52) | OPRD1OPRM1OPRK1MRGPRX2LMNA | |
| Thebacon SCHEMBL21304123 | 0.86 | OPRD1 (0.63) | OPRD1OPRM1OPRK1MRGPRX2LMNA | |
| Thebacon SCHEMBL1649199 | 0.86 | OPRD1 (0.63) | OPRD1OPRM1OPRK1MRGPRX2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200038383-A1 | IMMEDIATE-RELEASE ABUSE DETERRENT COMPOSITIONS OR MEDICAMENTS FOR TREATING PAIN, ADD, ADHD AND OTHER SYNDROMES OR DISORDERS | ALTER DOMUS (US) LLC | 2020-02-06 | — | — | US | disclosed |
| WO-2018071879-A1 | IMMEDIATE-RELEASE ABUSE DETERRENT COMPOSITIONS OR MEDICAMENTS FOR TREATING PAIN, ADD, ADHD AND OTHER SYNDROMES OR DISORDERS | KEMPHARM, INC. (US) | 2018-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200038383-A1 | IMMEDIATE-RELEASE ABUSE DETERRENT COMPOSITIONS OR MEDICAMENTS FOR TREATING PAIN, ADD, ADHD AND OTHER SYNDROMES OR DISORDERS | OPRK1, OPRL1, OPRD1 | OPRD1 3/4885OPRM1 4/4885OPRK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.